Abiraterone oral - Bukwang Pharmaceuticals

Drug Profile

Abiraterone oral - Bukwang Pharmaceuticals

Alternative Names: SOL-804

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solural Pharma
  • Class Antiandrogens; Antineoplastics
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 04 Oct 2017 Bukwamg Pharmaceuticals plans a phase I trial for Prostate cancer (Bunkwang Pharmaceuticals pipeline, October 2017)
  • 08 Dec 2015 SOL 804 is available for licensing as of 08 Dec 2015. http://soluralpharma.com/project/
  • 08 Dec 2015 Preclinical trials in Prostate cancer in Denmark (PO) prior to December 2015 (Solural pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top